Balancing Accelerated Approval for Drugs With Accelerated Withdrawal Reply

被引：0
|
作者：
Kim, Chul [1 ]
Prasad, Vinay [2 ,3 ]
机构：
[1] NCI, Med Oncol Serv, NIH, Bethesda, MD 20892 USA
[2] Oregon Hlth & Sci Univ, Div Hematol Oncol, Knight Canc Inst, Portland, OR 97239 USA
[3] Oregon Hlth & Sci Univ, Ctr Hlth Care Eth, Portland, OR 97239 USA
来源：
JAMA INTERNAL MEDICINE | 2016年 / 176卷 / 04期
关键词：
D O I：
10.1001/jamainternmed.2016.0374
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：567 / 567
页数：1
相关论文
共 50 条
  • [31] The Accelerated Drug Approval
    Novack, Gary D.
    OCULAR SURFACE, 2010, 8 (04): : 205 - 206
  • [32] Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
    Gyawali, Bishal
    Hey, Spencer Phillips
    Kesselheim, Aaron S.
    JAMA INTERNAL MEDICINE, 2019, 179 (07) : 906 - 913
  • [33] Reforming accelerated approval
    Nature Biotechnology, 2012, 30 : 293 - 293
  • [34] Accelerated approval for ofatumumab
    不详
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (02) : 262 - 262
  • [35] Accelerated approval for nevirapine
    Firshein, J
    LANCET, 1996, 347 (9017): : 1755 - 1755
  • [36] Accelerated Approval of Oncology Drugs: Can We Do Better?
    Ellenberg, Susan S.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (08) : 616 - U106
  • [37] Anatomy of an FDA Drug Recall: The 17α-Hydroxyprogesterone Accelerated Approval and Withdrawal Processes
    Norwitz, Errol R.
    Norwitz, Gabriella A.
    Diaz, Angela M.
    Davis, Jonathan
    CURRENT OBSTETRICS AND GYNECOLOGY REPORTS, 2024, 13 (03): : 171 - 179
  • [38] TIME TO APPROVAL OF NOVEL CANCER MEDICINES GRANTED ACCELERATED APPROVAL AND IMPLICATIONS FOR REFORM OF THE ACCELERATED APPROVAL PATHWAY
    Hwang, Thomas
    Tibau, Ariadna
    JOURNAL OF UROLOGY, 2024, 211 (05): : E941 - E941
  • [39] Global consequences of the US FDA's accelerated approval of cancer drugs
    Akhade, Amol
    Sirohi, Bhawna
    Gyawali, Bishal
    LANCET ONCOLOGY, 2022, 23 (02): : 201 - 203
  • [40] Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits
    Sachs, Rachel E.
    Jazowski, Shelley A.
    Gavulic, Kyle A.
    Donohue, Julie M.
    Dusetzina, Stacie B.
    JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2022, 47 (06) : 673 - 690
12345